During LAI oral dosing week 1, dosing should be increased to what for week 2?

During LAI oral dosing week 1, dosing should be increased to what for week 2?

• A. 0.5 mg BID
• B. 1 mg BID
• C. 3 mg BID
• D. 4 mg daily

Answer: (B)

The key idea is titrating the oral lead-in to achieve a balance between tolerability and adequate antiviral exposure before starting the long-acting injections. Starting at a lower amount in week one helps assess tolerability, and increasing to the higher dose in week two ensures plasma levels are sufficient to sustain viral suppression during the transition to injections. The week-two dose of 1 mg twice daily provides the necessary exposure without unnecessary excess that could raise the risk of adverse effects; subtherapeutic dosing like 0.5 mg twice daily could risk inadequate activity, while much higher doses (such as 3 mg twice daily or 4 mg daily) aren’t necessary for this short lead-in period and don’t add benefit in this context.

The key idea is titrating the oral lead-in to achieve a balance between tolerability and adequate antiviral exposure before starting the long-acting injections. Starting at a lower amount in week one helps assess tolerability, and increasing to the higher dose in week two ensures plasma levels are sufficient to sustain viral suppression during the transition to injections. The week-two dose of 1 mg twice daily provides the necessary exposure without unnecessary excess that could raise the risk of adverse effects; subtherapeutic dosing like 0.5 mg twice daily could risk inadequate activity, while much higher doses (such as 3 mg twice daily or 4 mg daily) aren’t necessary for this short lead-in period and don’t add benefit in this context.